Efficacy and Safety of Hirudotherapy for Improving Sperm Quality Parameters in Male Infertility: A Randomized Controlled Trial
Abtahi-Forooshani MS, Roozbehani S, Fatemi M, Noori A (2026) · Health Science Reports · n=50
- Abtahi-Forooshani MS 202650
- Cheng SP 200544
Study Profile
- Design
- single-center, parallel-group, open-label randomized controlled trial of hirudotherapy versus no-intervention control in idiopathic male infertility (Fal.C. Islamic Azad University, Isfahan, Iran)
- Sample size (n)
- 50
- Intervention
- Weekly Hirudo medicinalis leech therapy for 3 months (n=25); semen parameters assessed at baseline and end of intervention
- Comparator
- No-intervention control group (n=25) with semen parameters assessed at the same time points
- Primary endpoint
- Sperm concentration, total sperm count, progressive motility, normal morphology (WHO criteria), sperm DNA fragmentation (TUNEL assay), protamine deficiency (chromomycin A3 staining), and sperm viability/morphology by flow cytometry
- Primary result
- Sperm concentration increased from 57.7±17.1 to 63.4±13.1 million/mL in the leech arm (p=0.006); total count, progressive motility, and normal morphology all improved significantly vs control (p<0.05); DNA fragmentation decreased by 3.9% in leech arm vs control (p=0.04); protamine deficiency reduced (p=0.02); no adverse events reported
- Follow-up duration
- 3 months (12 weekly sessions plus end-of-intervention semen analysis)
- PMID
- 41743152
Key Findings
- First PubMed-indexed RCT of medicinal leech therapy for male infertility sperm quality parameters
- Statistically significant improvement in sperm concentration, motility, morphology, and DNA integrity in the leech arm vs no-treatment control
- DNA fragmentation reduction of ~4% in the leech arm — biologically plausible mechanism via systemic anti-inflammatory and microcirculatory effects
- No reported adverse events across 12 weekly sessions over 3 months
- Iranian Registry of Clinical Trials registration (IRCT20230502058045N) supports transparency
Limitations
- Small sample (n=50, only 25 per arm) limits subgroup analysis and effect-size precision
- Open-label design with no-intervention control — placebo, expectancy, and lifestyle-change effects cannot be excluded
- Single-center Iranian trial — generalizability to other infertility populations untested
- No pregnancy or live-birth outcomes reported; biomarker-only endpoints
- Mechanism speculative — no measurement of inflammatory markers, oxidative stress, or testicular blood flow to support causal pathway
Clinical Implications
Abtahi-Forooshani 2026 is the first randomized hirudotherapy trial in male infertility and provides preliminary biomarker-level evidence that 12 weekly leech sessions may improve sperm quality parameters in idiopathic infertility. For US clinicians, the trial is investigational only and does not support routine use — male infertility is not among K040187-cleared indications and the open-label design leaves substantial uncertainty. The trial does add an emerging Iranian dimension to the global hirudotherapy evidence base and motivates double-blind sham-controlled replication with downstream fertility outcomes (pregnancy, live birth) before any clinical translation can be considered.
Related studies
Effectiveness of topical gel of medical leech (Hirudo medicinalis) saliva extract on patients with knee osteoarthritis: a randomized clinical trial
Shakouri A, Adljouy N, Balkani S, Mohamadi M, Hamishehkar H, Abdolalizadeh J, Kazem Shakouri S (2017)
Efficacy of Medicinal Leech Therapy in Diverse Clinical Applications: A Comprehensive Study from Azerbaijan
Farzali S, Yaraliyeva S, Huseynov F, Manafov A, Saglam N (2025)